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High-throughput interaction discovery initiatives are providing thousands of novel protein interac-
tions which are unveiling many unexpected links between apparently unrelated biological pro-
cesses. In particular, analyses of the ﬁrst draft human interactomes highlight a strong association
between protein network connectivity and disease. Indeed, recent exciting studies have exploited
the information contained within protein networks to disclose some of the molecular mechanisms
underlying complex pathological processes. These ﬁndings suggest that both protein–protein inter-
actions and the networks themselves could emerge as a new class of targetable entities, boosting the
quest for novel therapeutic strategies.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
For over a decade, genome-sequencing projects have been
delivering nearly complete lists of the genes and gene products
present in many organisms, including human [1,2]. However, taken
individually, these components reveal relatively little about how
complex biological systems organize the many discrete functions
needed for survival. Virtually every process in a cell is performed
by macromolecular complexes, often composed of many protein
components, and regulated through the coordination of an intri-
cate network of transient protein–protein interactions. It is thus
the relationships between molecules what will ultimately deter-
mine the behavior of the system and, consequently, big efforts
have been devoted to the large-scale identiﬁcation of new protein
interactions and macromolecular complexes.
The most widely used experimental techniques in high-
throughput interaction discovery are yeast two-hybrid assays [3]
and binding afﬁnity puriﬁcations coupled to mass spectrometry
analyses [4], in their many different ﬂavors (e.g. [5,6]). A system
based on simple genetic manipulation with relatively easy read-
outs has made these two methodologies readily applicable to
whole genomes of some of the major model organisms [7–12]
and to a large fraction of human proteome [13,14]. Despite the
clear success of large-scale interaction discovery initiatives, whichchemical Societies. Published by E
rch in Biomedicine (IRB) and
ixac 10-12, 08028 Barcelona,
loy).have revealed thousands of unexpected interactions, the poor
overlap observed between different screens run on the same
organism [8,15] promoted the conception that their results are
too dirty to be applicable. It has taken the community a decade
of intense research to retaliate this notion and ﬁnally, recent stud-
ies have provided a general framework to correctly interpret the
outcome of high-throughput interaction discovery experiments
[16,17]. Today, protein interaction maps are of enough quality to
become very valuable tools to help in the understanding of the
underlying mechanisms of life, and we anticipate that they will
play a pivotal role in the future of biological and biomedical
research.
In this manuscript, we explore the relationship between protein
interaction networks and human disease and review recent discov-
eries in the ﬁeld of network biology that have contributed to gain a
deeper knowledge of the molecular bases of pathological pro-
cesses. Moreover, and perhaps more importantly, we discuss how
these ﬁndings can be readily translated into novel therapeutic
strategies to ﬁght complex diseases.2. The role of connectivity in human disease
Several human genetic diseases are caused by one or more
mutations on a single gene, showing a Mendelian inheritance pat-
tern, while the onset and the progression of others depend on the
interplay of many causative genes. However, it has been suggested
that this categorization might be an oversimpliﬁcation [18,19].
Many well-established monogenic diseases, such as Phenylketon-
uria and Cystic Fibrosis, are actually oligogenic, meaning that therelsevier B.V. All rights reserved.
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trait inherited by one gene [20]. There is also convincing evidence
indicating that the causative genes, in both oligogenic and complex
diseases, do not usually have isolated cellular functions but they
rather work together in the same biological module or pathway
[20,21], which highlights a strong link between protein connectiv-
ity and disease (Table 1).
Early structural studies showed that, at least for a small set of
disease genes tested, the onset of a disorder phenotype is related
to mutations that may perturb the quaternary structure of the dis-
ease proteins and therefore disrupt protein interactions [22]. More
recently, Schuster-Boeckler and Bateman compiled a list of 199
manually curated mutations in 65 diseases which do alter the
interaction ability of the proteins affected [23]. The authors classi-
ﬁed these mutations according to whether they suppress or add
interactions in the protein connectivity, resulting into a loss of
function (LOF) or a gain of function (GOF) (Fig. 1). Most of the con-
sidered mutations showed a LOF by mainly disrupting transient
protein–protein interactions. For instance, a mutation in BRCA2, a
breast cancer related gene, impairs the interaction with the repli-
cation protein A complex, essential for DNA repair [24], which
leads to an accumulation of carcinogenic DNA damages. Another
case of a LOF mutation occurs in the von Hippel–Lindau (VHL) tu-
mor suppressor gene involved in the VHL syndrome, an inherited
predisposition to a variety of cancer types [25]. A common VHL
mutation disrupts the interaction with the hypoxia-inducible tran-
scription factor, which is then no longer degraded, causing the
expression of angiogenic growth factors that promote local prolif-
eration of blood vessels [26].
Fewer than twenty mutations resulted in GOF, which can be di-
vided into pathological aggregation and aberrant recognition
mutations. To the ﬁrst group belong mutations related to amyloidTable 1
Collection of human diseases directly related to changes in the associated interaction netw
gene products of Fanconi anemia and Usher syndrome are part of complexes involved
syndromes are caused by mutations in genes involved in the hedgehog pathway, whereas
Disease Functional
relationship
Description
Fanconi anemia Protein complex Mutated genes are involv
Usher syndrome Protein complex Causative genes form a c
von Hippel–Lindau syndrome Protein complex Mutation in VHL gene di
transcription factor, HIF
Inherited ataxias Interaction sub-
network
Causative genes are part
Congenital malformation
syndromes
Pathway Mutated genes are part o
Bone-mass related diseases Pathway Disease onset is associat
Osteoarthritis Pathway Causative gene is part of
Fig. 1. Mutations in disease genes may alter their interaction properties and therefor
interface leading to loss of function (LOF) effect, whereas other mutations modify the indiseases like Alzheimer’s but also sickle cell anemia, for instance.
One case of aberrant recognition mutations is represented by a sin-
gle amino acid substitution that increases the binding afﬁnity of
the glycoprotein GP1BA with the von Willebrand factor, leading
to von Willebrand disease, a bleeding disorder [27].
Individual examples are always illustrative but, to extract rele-
vant conclusions, it is necessary to check whether the relationship
between protein connectivity and human disease is a general trend
or only a curiosity. Recently, the availability of human protein
interaction data from large-scale experiments [13,14] and litera-
ture mining [28,29], has permitted to study the network properties
of disease genes from a global perspective.
Several groups suggested that human inherited disease genes
tend to encode proteins that have a larger number of interactions
than non-disease-related proteins and that they preferentially
interact with other disease-causing genes [30–32], representing
thus the hubs in the interaction networks [33]. However, this
notion has been questioned by Goh and colleagues, who have
provided evidence that the ‘hub-ness’ of inherited disease genes
may be only apparent [31]. They showed that almost a ﬁfth of
inherited disease genes are essential for survival, meaning that
mutations in these genes are lethal, and thus they are not main-
tained at population level. When this set of essential genes are
removed from the analysis, the encoding hubs completely disap-
pear and non-essential disease genes tend to be located on the
periphery of the interaction network, giving the cell a higher
chance of survival [31]. On the other hand, disease genes whose
mutations are somatic (i.e. most cancer types) are not necessarily
subject to the evolutionary constraints that shape the topology of
interaction networks and thus, they are more likely to encode for
protein hubs [31,34,35] and to occur within the same sub-net-
work [35].orks. Disease proteins in complexes and pathways (adapted from [21]): the causative
in DNA repair and hair cell differentiation, respectively. Congenital malformation
bone-mass related diseases and osteoarthritis genes are part of the Wnt pathway.
Reference
ed in the functioning of DNA repair complex [87]
omplex involved in hair cell differentiation [88]
srupts the interaction with the hypoxia-inducible [26]
of a well connected interaction network [49]
f the hedgehog signaling pathway [89]
ed to mutations in a co-receptor of Wnt proteins [90]
the Wnt signaling pathway [91]
e perturb the network topology. Some of these mutations disrupt the interaction
teraction properties allowing the recruitment of novel partners (GOF).
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that has been noted is the change in the wiring and information
ﬂow that some cell types display whenmoving from healthy to dis-
ease states. Wolf-Yadlin and colleagues have shown this wiring ef-
fect on cells over-expressing HER2 (a member of the EGF receptor
family), which activate signaling networks controlling cell prolifer-
ation and migration that promote the phosphorylation of several
downstream effectors that are not activated when HER2 is ex-
pressed at normal physiological levels [36]. It has also been re-
ported that several pathways in the liver show a rewiring in the
receptor-nucleus downstream routes when comparing normal
hepatocytes with HepG2, a human hepatocellular liver carcinoma
cell line [37].3. Network-based approaches to understand human disease
In the recent years, technologies such as high-throughput gene
expression proﬁling [38] have permitted the characterization of
molecular differences between healthy and disease states, leading
to the identiﬁcation of an increasing number of disease-related
genes [39–42]. However, a clear limitation of these approaches is
that they often deal with data about single players (i.e. changes
in the expression of individual genes) and, to be most effective, no-
vel strategies should also integrate systemic information to con-
textualize the differential expression patterns observed. Lately,
protein network-based approaches have proved to be useful in
understating relevant disease-related biological processes, such
as inﬂammation [43], and identifying candidate disease genes
and biomarkers [44].
Partly because high-throughput interaction discovery initiatives
(e.g. [13,45]), there are a few human diseases for which we are able
to gather interaction data of enough quality to explain their under-
lying mechanisms. Chuang et al. [46] successfully applied a net-
work-based approach to show that known breast cancer genes
that do not change their expression proﬁle might still play a central
role interconnecting genes in the protein network whose transcrip-
tion is dysregulated in metastatic samples. They identiﬁed many
discriminative sub-networks that are signiﬁcantly more reproduc-
ible than individual marker genes selected without network infor-
mation, and that are also better classiﬁers of metastatic tumors.
More recently, Mani et al. [47] combined a weighted B-cell interac-
tome and a large set of microarray expression proﬁles to identify
dysregulated interactions in three different type of lymphomas.
By including network information in their study, they could suc-
cessfully identify both known and candidate oncogenes as well
as secondary effectors that could not be highlighted by conven-
tional analysis based on differential expression.
A prerequisite to conduct these analyses is the availability of
good quality interactome networks which, unfortunately, are still
missing for most human diseases, which means that most efforts
to unveil the molecular bases of these pathologies should necessar-
ily involve an initial interaction discovery step. To help closing this
information gap, Ewing and colleagues [48] recently conducted a
large-scale immunoprecipitation analysis followed by mass spec-
trometry and identiﬁed 6400 high-conﬁdence interactions of
special relevance in several human diseases. Additionally, different
research groups have focused their interest in charting the interac-
tion network of speciﬁc disorders to ﬁnd out putative disease
genes or novel modiﬁer genes involved in the control of the disease
phenotype. For instance, Lim and colleagues [49] built an interac-
tion network for ataxia-causing and ataxia-associated proteins
using yeast two-hybrid assays, and identiﬁed more than seven
hundred interactions, a subset of which has been also conﬁrmed
by co-afﬁnity puriﬁcations from mammalian cells. Moreover, they
reported that many ataxia-causing proteins cluster in a well-con-nected sub-network and share many interactors, some of which
proved to be ataxia modifying genes in animal models. Kaltenbach
et al. [50] applied a similar approach to identify interactors of the
Huntingtin protein, whose expansion of the polyQ tail leads to the
onset of Huntington’s disease (HD). From a deﬁned high-conﬁ-
dence set of roughly 200 interaction partners, they found that
45% of a randomly chosen subset of 60 interactors turned to act
as genetic modiﬁers of neurodegeneration in a HD ﬂy model. Cam-
argo et al. [51] also used yeast two-hybrid screens to generate an
interaction network around DISC1 protein, a well-established risk
factor for schizophrenia, which consisted of 158 interactions
among 127 proteins, many of which are located in schizophrenia
risk loci. Moreover, their ﬁndings proved that DISC1 and other
schizophrenia-related proteins are involved in synaptic function.
Perhaps the most illustrative work corresponds to the strategy fol-
lowed by Vidal and coworkers [52], who employed a combined ap-
proach based on computational modeling and experimental
techniques to identify genes that could be potentially associated
with higher risk of breast cancer. They constructed a breast cancer
network integrating several ‘omic’ datasets (both from human and
other organisms) containing 118 genes linked by 866 functional
associations. Through yeast two-hybrid and co-immunoprecipita-
tion assays, they validated and extended the breast cancer network
pinpointing putative disease players. Their gene association stud-
ies identiﬁed a genetic link between breast cancer susceptibility
and centrosome dysfunction.4. Targeting networks
We have seen that, for many diseases, there are increasing
pieces of evidence supporting the fact that their onset and progres-
sion arise from the interplay of a number of well-interconnected
causative genes. This novel perspective is shifting the gene-centric
paradigm of drug discovery towards a network/pathway-centric
approach [53].
A detailed interaction map of a given pathology can extend the
knowledge of disease mechanism [54] and can suggest potential
points for therapeutic intervention (i.e. drug targets). Using inter-
actome maps to select these strategic network nodes will permit
to consider the robustness of the system, which is not possible in
gene-centered approaches since they mostly disregard the target
biological context. Biological systems, such as disease states, are
generally resistant to perturbations and they are able to maintain
their functions through different mechanisms such as back-up cir-
cuits and fail-safe mechanisms (i.e. redundancy and diversity) [55].
Therefore, the selection process of new putative drug targets
should also consider the network positioning (i.e. involvement in
fewer pathways or on their topological properties), preferring
those enclaves that are essential to drive the network trafﬁc and
able to avoid back-up circuits that could neutralize the drug effect.
Another therapeutic front where we anticipate that network
biology approaches will make an impact is the identiﬁcation of
protein–protein interactions suitable to be directly targeted with
drug-like compounds [56,57]. Targeting interactions has certain
advantages over more traditional targets such as enzyme active
sites as it often offers a more subtle, speciﬁc form of regulation that
can avoid off-target side effects or total ablation of normal enzyme
activity. Nutlins, a class of drug cancer candidates, are a well-
known example because they block the interaction between the
tumor suppressor p53 an its negative regulator MDM2, which is
over-expressed in many cancer types, thus allowing p53 to carry
out its task in mediating apoptosis [58]. Many other chemicals
have been designed in order to disrupt the interaction among
translation initiation factors [59] or to sequestrate cytokines to im-
pede receptor binding [60]. Although it is difﬁcult to identify small
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[61]) and technical improvements will hopefully provide the nec-
essary toolkit to further expand this domain of drug discovery.
Besides the basic network wiring, target selection strategies
should also consider individual treats, such as the genetic diversity
of human population, since they contribute considerably to the
variability in drug action [62] affecting both the drug disposition
(pharmacokinetics) and the drug effect itself (pharmacodynamics)
[63]. Considering this type of information in the target selection
process will improve the effectiveness and the applicability of fu-
ture therapeutic treatments. Nevertheless, given the recent
improvements in genome sequencing techniques (e.g. [64,65]) it
is likely that decoding an individual genome will be affordable in
a few years, making personalized medicine a common practice.Fig. 2. Representation of the main drug target classes displayed as threedimensional str
drug targets. Kinases: protein kinases represent the 47% of current drugged families. GPCR
receptors, the 8%; ion channels: the 7%; transporters: the 4%; and others: targets which a5. Expanding the druggable space
The quest for new therapeutic agents often involves many com-
plex processes and, unfortunately, information on the molecular
wiring associated to a given disease, although crucial, it is often
insufﬁcient to develop a successful drug. Even for those cases
where the analysis of the disease network reveals potential points
of intervention, these selected nodes need to be modulated by
small drug-like molecules (i.e. they need to be druggable). Recent
studies have estimated the druggable genome roughly includes
3000 of the 30000 human genes which means that, on average,
only 10–15% of the proteins present in disease-associated interact-
omes will be amenable for being targeted with the current avail-
able chemistry [66]. The good news is that only 400 of theseuctures on a sized spiral distribution according to their frequency as FDA-approved
s: transmembrane G-protein-coupled receptors, the 30%; other receptors: non-GPCR
re not classiﬁed under any of the families mentioned above, the 4%.
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plenty of room for development of drugs against new targets. Fig. 2
gives an overview of the main protein classes currently used as
drug targets.
Disease biology is extremely complex and even when we iden-
tify a good drug target and a chemical modulator of its activity
with good pharmacological properties, there are things that can
go wrong. This has been the case for some of the most successful
drugs, like Genentech’s breast cancer treatment Herceptin and
Novartis’ leukaemia drug Gleevec, which eventually become inac-
tive in many patients because of gradually increasing resistance
of cancer cells [68]. It is thus not surprising that attempts to create
more effective treatments for polygenic diseases by developing
more selective and potent drugs for single molecular targets (the
so-called ‘magic bullets’) have been of limited success [69]. Some
speciﬁc drugs have been directed towards a target that resulted
not essential for the pathophysiology of the disease or designed
to interact with a single target that has generated unpredicted ef-
fects on off-target biochemical mechanisms [70]. An illustrative
example is the case of Rofecoxib [71], a COX2-inhibitor used for
mitigating inﬂammation. It was considered a promising drug be-
cause, compared to other anti-inﬂammatory agents, had a higher
selectively for COX2 over COX1, thus avoiding the common adverse
gastrointestinal effects. However, it showed a higher level of cross-
talk with other pathways in different tissues and displayed a high-
er risk of adverse cardiovascular events at high doses [72].
Indeed, recent analysis of drug and drug-target networks show
a rich pattern of interactions among drugs and their targets, where
drugs acting on single targets appear to be the exception. Likewise,
many proteins are targeted by more than one drug containing dis-
tinct chemical structures [34,73–75]. Consequently, a concept that
is increasingly gaining adepts is that of polypharmacology, both
from target and drug perspectives. On the one hand, the analysis
of the biological networks associated to a given disease can suggest
multiple targets to achieve the desired outcome. But on the other
hand, we can also envisage new molecules speciﬁcally synthesized
from building block that should confer them the capacity to bind
multiple targets with low speciﬁcity (i.e. ‘magic shotguns’ or ‘dirty
drugs’) This polypharmacology strategy has already been success-
fully applied to some CNS disorders [69], Alzheimer’s Disease [76],
oncogenic mutations [77], and it looks very promising for the iden-
tiﬁcation of effective antibacterial drugs [78]. Similarly, multi-tar-
get antibodies (in forms of diabodies, triabodies, tetrabodies and
recombinant polyclonal antibodies) are also increasingly used in
cancer therapy to delay the development of resistance [79]. The
efﬁcacy of such therapies can be explained by the fact that drugs
targeting different proteins in the disease network or pathway
could trigger a more-than-additive effect, and that their combina-
tion can eliminate compensatory reactions, avoiding thus a drug-
resistance denouement [80]. Moreover, if we hit the disease from
different fronts, it is likely that we would not need to be highly
effective in depleting the function of each single target, meaning
that we could reduce the dose of each drug and circumvent some
dose-related adverse events.
Another strategy that is becoming increasingly important in
drug development, due to the difﬁculty in obtaining active drug-
like molecules with acceptable side effects, consists of ﬁnding of
new therapeutic uses for already approved drugs, an activity re-
ferred to as ‘drug repurposing’. This approach blindly screens exist-
ing compounds against a multitude of targets, and identiﬁes either
possible therapeutic beneﬁts or side effects in a unbiased manner
[81]. For instance, by testing thousands of combinations of off-pat-
ent drugs in cell-based assays, it has been found that two drugs
with different indications (an antipsycothic and an antiprotozoal)
exhibit an unexpected anti-tumoral activity [82]. A similar analysis
was recently developed by measuring the side-effect similarity ofmarketed drugs to identify potential new targets [83]. However,
repositioning implies unique challenges like identiﬁcation and val-
idation of the candidate from incomplete or outdated data, devel-
opment of novel clinical trials for indications that have never been
pursued before, and overcoming patents that could block commer-
cialization [84].
The analysis of disease networks has also permitted the discov-
ery of novel classes of therapeutic targets not amenable to classical
drug-like compounds but reachable through novel bioactive com-
pounds. Indeed, new biotherapeutics already make up the majority
of FDA approved biotechnology medicines, including therapeutic
proteins, monoclonal antibodies, antibody fragments, stem cells,
antisense oligonucleotides and other RNA therapeutics [85]. Bio-
therapeutics have several advantages over small-molecule drugs
as they often act through highly speciﬁc and complex functions
that cannot be mimicked by simple chemical compounds. More-
over, they are produced in high amounts by the human body and
by other organisms, which converts them in safer and less toxic
agents. As a drawback, their pharmacology characteristics are gen-
erally quite different from those of small-molecule drugs, which
may complicate drug development and clinical use [86].6. Concluding remarks
Current versions of the basic wiring diagrams of eukaryotic cells
are still far from complete and prone to many errors. Nevertheless,
recent studies have shown that, when combined with other biolog-
ical data and computational tools, they contain enough informa-
tion to largely enhance our understanding of the underlying
mechanisms of life. Recent successes in the network biology ﬁeld,
such as the ones reviewed here, have attracted the interest of bio-
tech and pharmaceutical companies that see how a strategy
change towards more systemic approaches might increase the rev-
enues of the drug discovery process. A deeper knowledge of the cell
networks and molecular bases that drive pathological processes
will inspire novel therapeutic strategies, ultimately leading to the
development of more effective and safer drugs to ﬁght complex
diseases.
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